<DOC>
	<DOCNO>NCT00132379</DOCNO>
	<brief_summary>The drug ABR-217620 combination two protein , one recognize tumor cell one trigger attack tumor cell activate white blood cell belong body 's normal immune system . In animal , result accumulation white blood cell cancer fight cancer . This study test much drug , combination docetaxel ( approve drug treat non-small cell lung cancer [ NSCLC ] ) , give patient NSCLC without cause unacceptable side effect .</brief_summary>
	<brief_title>ABR-217620 Combination With Docetaxel Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Patients histologically cytologically confirm advanced NSCLC progress first line platinbased therapy fail treatment regimen decline standard regimen . ECOG performance status 0 1 . Adequate bone marrow function : absolute neutrophil count great equal 1500/mm3 ; WBC great equal 3000/mm3 ; platelet great equal 100,000/mm3 ; hemoglobin great equal 10 g/dL . Adequate renal function : creatinine le equal 1.5 x upper limit normal ( ULN ) . Adequate hepatic function : bilirubin le ULN ; SGOT ( AST ) SGPT ( ALT ) less 1.5 x ULN concomitant alkaline phosphatase ( ALP ) less 2.5 ULN . Female patient pregnant nursing planning become pregnant study . Fertile , sexually active woman willing practice reliable contraception . Male patient partner childbearing potential use acceptable contraceptive method . A serious uncontrolled medical disorder active infection include unexplained fever ( temperature great 100.5 degree Fahrenheit 38.1 degree Celsius ) would impair patient 's ability receive study treatment . Any concurrent malignancy , except follow malignancy may include : nonmelanoma skin cancer ; cervical cancer situ ; ductal carcinoma situ ( DCIS ) lobular carcinoma situ ( LCIS ) breast ; past history prostate cancer without clinical evidence disease ( include patient receive hormonal therapy ) . History brain metastasis , unless stable 4 week , require steroid therapy without clinical symptom brain metastasis . Significant symptomatic cardiac disease include history ( within past 6 month ) current unstable angina , congestive heart failure , myocardial infarction ; patient uncontrolled hypertension , hypertension require treatment 2 drug . History current arrhythmia require treatment , except nonspecific , asymptomatic STT wave change extrasystoles . Seizure disorder require therapy . Treatment betablockers , include topical therapy glaucoma , 6day treatment period ( 5day treatment + 1 day inpatient followup ) , within 5 day start ABR217620 treatment . Simultaneous participation investigational drug study participation study le 4 week start study treatment . Treatment systemic inhale corticosteroid within 2 week start treatment . Treatment anticoagulant , except use maintain patency central venous line . Active autoimmune disease require therapy history systemic lupus erythematosus rheumatoid arthritis . Concurrent biological response modifier ( within 3 week study entry ) except type erythropoetin . Chemo/radio/immunotherapy le 4 week ( 6 week mitomycin C nitrosoureas ) start treatment . Known allergy hypersensitivity reaction aminoglycosides ( e.g. , kanamycin ) . Known allergy hypersensitivity reaction docetaxel drug formulate polysorbate 80 . Previous exposure murine monoclonal antibody ( human antimouse antibody [ HAMA ] titer detection limit baseline ) know hypersensitivity murine protein . Major surgery within 3 week . Known history HIV infection . Known chronic hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>